Skip to main content
Top
Published in: Dermatology and Therapy 8/2023

Open Access 15-07-2023 | Vulgar Psoriasis | Original Research

Treatment Preferences in Young Adults with Moderate to Severe Psoriasis: A Qualitative Study from the Nordic Countries

Authors: Flora Nicol Balieva, Louise Catton, Birgitta W. Claréus, Kjersti Danielsen, Frederik Fierens, Lars Iversen, Leena Koulu, Amra Osmanecevic, Rafael Pasternack, Lone Skov

Published in: Dermatology and Therapy | Issue 8/2023

Login to get access

Abstract

Introduction

The purpose of this study is to explore treatment preferences and identify patient characteristics in young bio-naive adults with moderate to severe psoriasis in the Nordic countries (Norway, Finland, Sweden, and Denmark).

Methods

Patients were 18–45 years old and bio-naive but referred for biologic treatment of moderate to severe psoriasis. Patients were included at eight Nordic dermatology clinics. Patients with significant comorbidity or psoriatic arthritis were excluded. The Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were assessed along with basic patient information.
A semistructured interview guide was used in individual qualitative interviews, asking patients about their treatment preferences and reasons, disease journey, and disease management. The interviews were analyzed using thematic content analysis. Twenty-four patients sufficed to reach saturation in this qualitative study.

Results

The patient sample characteristics represented a qualitative variation in age, sex, symptoms, duration of disease, and country. We included a total of 12 male and 12 female patients. The mean age was 34 years (range 18–45 years), the mean age at diagnosis was 20 years (range 6–34 years), the mean ± standard deviation (SD) time since diagnosis was 13 ± 8 years, PASI was 9.5 ± 4.7, and DLQI was 15.2 ± 6.4.
Interviews suggested that both the burden of disease as well as the burden of treatment influenced patient preferences regarding treatment attributes, hence getting alleviation from symptoms did not alone influence patient preferences. Time, effort, and inconvenience related to psoriasis treatments also influenced patient preferences.

Conclusions

This first in-depth, qualitative study in young bio-naive adults with psoriasis suggests that patient preferences are focusing not only on symptom relief but also on alleviating the burden of psoriasis treatment. Understanding the reasons for patient preferences and the perspectives of young adults is needed to guide individual shared decision-making in psoriasis management.
Appendix
Available only for authorised users
Literature
1.
go back to reference Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–51.CrossRefPubMed Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–51.CrossRefPubMed
2.
go back to reference Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–90.CrossRefPubMedPubMedCentral Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–90.CrossRefPubMedPubMedCentral
3.
go back to reference Danielsen K, Duvetorp A, Iversen L, Østergaard M, Seifert O, Tveit KS, et al. Prevalence of psoriasis and psoriatic arthritis and patient perceptions of severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. Acta Derm Venereol. 2019;99(1):18–25.PubMed Danielsen K, Duvetorp A, Iversen L, Østergaard M, Seifert O, Tveit KS, et al. Prevalence of psoriasis and psoriatic arthritis and patient perceptions of severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. Acta Derm Venereol. 2019;99(1):18–25.PubMed
4.
go back to reference Ragnarson Tennvall G, Hjortsberg C, Bjarnason A, Gniadecki R, Heikkilä H, Jemec GB, et al. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. Acta Derm Venereol. 2013;93(4):442–5.CrossRefPubMed Ragnarson Tennvall G, Hjortsberg C, Bjarnason A, Gniadecki R, Heikkilä H, Jemec GB, et al. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. Acta Derm Venereol. 2013;93(4):442–5.CrossRefPubMed
5.
go back to reference Rasmussen MK, Enger M, Dahlborn AK, Juvik S, Fagerhed L, Dodge R, et al. The importance of achieving clear or almost clear skin for patients: results from the Nordic countries of the global. Acta Derm Venereol. 2019;99(2):158–63.CrossRefPubMed Rasmussen MK, Enger M, Dahlborn AK, Juvik S, Fagerhed L, Dodge R, et al. The importance of achieving clear or almost clear skin for patients: results from the Nordic countries of the global. Acta Derm Venereol. 2019;99(2):158–63.CrossRefPubMed
6.
go back to reference Tveit KS, Duvetorp A, Østergaard M, Skov L, Danielsen K, Iversen L, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol. 2019;33(2):340–54.CrossRefPubMed Tveit KS, Duvetorp A, Østergaard M, Skov L, Danielsen K, Iversen L, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol. 2019;33(2):340–54.CrossRefPubMed
7.
go back to reference Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–44.CrossRefPubMed Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–44.CrossRefPubMed
8.
go back to reference Bożek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851–6.CrossRefPubMed Bożek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851–6.CrossRefPubMed
9.
go back to reference Jankowiak B, Kowalewska B, Krajewska-Kułak E, Khvorik DF. Stigmatization and quality of life in patients with psoriasis. Dermatol Ther (Heidelb). 2020;10(2):285–96.CrossRefPubMed Jankowiak B, Kowalewska B, Krajewska-Kułak E, Khvorik DF. Stigmatization and quality of life in patients with psoriasis. Dermatol Ther (Heidelb). 2020;10(2):285–96.CrossRefPubMed
10.
go back to reference Jankowiak B, Kowalewska B, Krajewska-Kułak E, Khvorik DF, Niczyporuk W. Relationship between self-esteem and stigmatization in psoriasis patients. Postepy Dermatol Alergol. 2020;37(4):597–602.CrossRefPubMedPubMedCentral Jankowiak B, Kowalewska B, Krajewska-Kułak E, Khvorik DF, Niczyporuk W. Relationship between self-esteem and stigmatization in psoriasis patients. Postepy Dermatol Alergol. 2020;37(4):597–602.CrossRefPubMedPubMedCentral
11.
go back to reference Sojević Timotijević Z, Majcan P, Trajković G, Relić M, Novaković T, Mirković M, et al. The impact of changes in psoriasis area and severity index by body region on quality of life in patients with psoriasis. Acta Dermatovenerol Croat. 2017;25(3):215–22.PubMed Sojević Timotijević Z, Majcan P, Trajković G, Relić M, Novaković T, Mirković M, et al. The impact of changes in psoriasis area and severity index by body region on quality of life in patients with psoriasis. Acta Dermatovenerol Croat. 2017;25(3):215–22.PubMed
12.
go back to reference Obradors M, Blanch C, Comellas M, Figueras M, Lizan L. Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Qual Life Res. 2016;25(11):2739–54.CrossRefPubMed Obradors M, Blanch C, Comellas M, Figueras M, Lizan L. Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Qual Life Res. 2016;25(11):2739–54.CrossRefPubMed
13.
go back to reference Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014;20(8):13030/qt48r4w8h2. Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014;20(8):13030/qt48r4w8h2.
14.
go back to reference Hesselvig JH, Egeberg A, Loft ND, Zachariae C, Kofoed K, Skov L. Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis treated with ustekinumab. Acta Derm Venereol. 2018;98(3):335–9.CrossRefPubMed Hesselvig JH, Egeberg A, Loft ND, Zachariae C, Kofoed K, Skov L. Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis treated with ustekinumab. Acta Derm Venereol. 2018;98(3):335–9.CrossRefPubMed
15.
go back to reference Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. Br J Dermatol. 2020;182(4):965–73.CrossRefPubMed Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. Br J Dermatol. 2020;182(4):965–73.CrossRefPubMed
16.
go back to reference Pistone G, Gurreri R, Tilotta G, Caruso P, Curiale S, Bongiorno MR. Timing of quality of life improvements in psoriatic patients treated with different systemic therapies. Dermatol Ther. 2019;32(5): e13021.CrossRefPubMed Pistone G, Gurreri R, Tilotta G, Caruso P, Curiale S, Bongiorno MR. Timing of quality of life improvements in psoriatic patients treated with different systemic therapies. Dermatol Ther. 2019;32(5): e13021.CrossRefPubMed
17.
go back to reference Randa H, Lomholt JJ, Skov L, Zachariae R. Health-related quality of life in adolescents with psoriasis: an interview-based study. Br J Dermatol. 2018;178(6):1404–11.CrossRefPubMed Randa H, Lomholt JJ, Skov L, Zachariae R. Health-related quality of life in adolescents with psoriasis: an interview-based study. Br J Dermatol. 2018;178(6):1404–11.CrossRefPubMed
18.
go back to reference Raval K, Lofland JH, Waters H, Piech CT. Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol. 2011;10(2):189–96.PubMed Raval K, Lofland JH, Waters H, Piech CT. Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol. 2011;10(2):189–96.PubMed
19.
go back to reference EADV. Euroguiderm guideline for the treatment of psoriasis vulgaris. Syst Treat. 2021;35:281–317. EADV. Euroguiderm guideline for the treatment of psoriasis vulgaris. Syst Treat. 2021;35:281–317.
20.
go back to reference Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271–319.CrossRefPubMed Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271–319.CrossRefPubMed
21.
go back to reference Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis—a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700–8.CrossRefPubMed Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis—a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700–8.CrossRefPubMed
22.
go back to reference Wolf P, Weger W, Legat F, Painsi C, Saxinger W, Müllegger R, et al. Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross-sectional survey. J Dtsch Dermatol Ges. 2018;16(8):981–90.PubMed Wolf P, Weger W, Legat F, Painsi C, Saxinger W, Müllegger R, et al. Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross-sectional survey. J Dtsch Dermatol Ges. 2018;16(8):981–90.PubMed
23.
go back to reference de Vere Hunt IJ, McNiven A, Roberts A, Parmar H, McPherson T. ’Not just a piece of skin in front of you’-a qualitative exploration of the experiences of adolescents with eczema and psoriasis with healthcare professionals. BMJ Open. 2021;11(1): e041108.CrossRefPubMedPubMedCentral de Vere Hunt IJ, McNiven A, Roberts A, Parmar H, McPherson T. ’Not just a piece of skin in front of you’-a qualitative exploration of the experiences of adolescents with eczema and psoriasis with healthcare professionals. BMJ Open. 2021;11(1): e041108.CrossRefPubMedPubMedCentral
24.
go back to reference Newi AL, Tsianakas A, von Martial S, Sommer R, Blome C. How important is subjective well-being for patients? A qualitative interview study of people with psoriasis. Qual Life Res. 2022;31(12):3355–63.CrossRefPubMedPubMedCentral Newi AL, Tsianakas A, von Martial S, Sommer R, Blome C. How important is subjective well-being for patients? A qualitative interview study of people with psoriasis. Qual Life Res. 2022;31(12):3355–63.CrossRefPubMedPubMedCentral
25.
go back to reference Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893–907.CrossRefPubMed Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893–907.CrossRefPubMed
27.
28.
go back to reference Blome C, von Usslar K, Augustin M. Feasibility of using qualitative interviews to explore patients’ treatment goals: experience from dermatology. Patient. 2016;9(3):261–9.CrossRefPubMed Blome C, von Usslar K, Augustin M. Feasibility of using qualitative interviews to explore patients’ treatment goals: experience from dermatology. Patient. 2016;9(3):261–9.CrossRefPubMed
29.
go back to reference Miles MBHAM. Qualitative data analysis: an expanded sourcebook. Thousand Oaks: Sage Publications; 1994. Miles MBHAM. Qualitative data analysis: an expanded sourcebook. Thousand Oaks: Sage Publications; 1994.
31.
go back to reference Schaarschmidt ML, Umar N, Schmieder A, Terris DD, Goebeler M, Goerdt S, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27(2):187–98.CrossRefPubMed Schaarschmidt ML, Umar N, Schmieder A, Terris DD, Goebeler M, Goerdt S, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27(2):187–98.CrossRefPubMed
32.
go back to reference Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–67.CrossRefPubMedPubMedCentral Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–67.CrossRefPubMedPubMedCentral
33.
go back to reference Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–20.CrossRefPubMed Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–20.CrossRefPubMed
34.
go back to reference Schaarschmidt ML, Herr R, Gutknecht M, Wroblewska K, Gerdes S, Sticherling M, et al. Patients’ and physicians’ preferences for systemic psoriasis treatments: a Nationwide Comparative Discrete Choice Experiment (PsoCompare). Acta Derm Venereol. 2018;98(2):200–5.CrossRefPubMed Schaarschmidt ML, Herr R, Gutknecht M, Wroblewska K, Gerdes S, Sticherling M, et al. Patients’ and physicians’ preferences for systemic psoriasis treatments: a Nationwide Comparative Discrete Choice Experiment (PsoCompare). Acta Derm Venereol. 2018;98(2):200–5.CrossRefPubMed
35.
go back to reference Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69–78.CrossRefPubMed Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69–78.CrossRefPubMed
36.
go back to reference Gorelick J, Shrom D, Sikand K, Renda L, Burge R, Dworkin C, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a Cross-Sectional Patient Survey. Dermatol Ther (Heidelb). 2019;9(4):785–97.CrossRefPubMed Gorelick J, Shrom D, Sikand K, Renda L, Burge R, Dworkin C, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a Cross-Sectional Patient Survey. Dermatol Ther (Heidelb). 2019;9(4):785–97.CrossRefPubMed
37.
go back to reference Strohal R, Prinz JC, Girolomoni G, Nast A. A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus. J Eur Acad Dermatol Venereol. 2015;29(12):2390–8.CrossRefPubMedPubMedCentral Strohal R, Prinz JC, Girolomoni G, Nast A. A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus. J Eur Acad Dermatol Venereol. 2015;29(12):2390–8.CrossRefPubMedPubMedCentral
38.
go back to reference Rigopoulos D, Ioannides D, Chaidemenos G, Kallidis P, Voultsidou A, Matekovits A, et al. Patient preference study for different characteristics of systemic psoriasis treatments (Protimisis). Dermatol Ther. 2018;31(3): e12592.CrossRefPubMed Rigopoulos D, Ioannides D, Chaidemenos G, Kallidis P, Voultsidou A, Matekovits A, et al. Patient preference study for different characteristics of systemic psoriasis treatments (Protimisis). Dermatol Ther. 2018;31(3): e12592.CrossRefPubMed
39.
go back to reference Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics. 2014;32(2):209–23.CrossRefPubMed Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics. 2014;32(2):209–23.CrossRefPubMed
Metadata
Title
Treatment Preferences in Young Adults with Moderate to Severe Psoriasis: A Qualitative Study from the Nordic Countries
Authors
Flora Nicol Balieva
Louise Catton
Birgitta W. Claréus
Kjersti Danielsen
Frederik Fierens
Lars Iversen
Leena Koulu
Amra Osmanecevic
Rafael Pasternack
Lone Skov
Publication date
15-07-2023
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 8/2023
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-023-00973-5

Other articles of this Issue 8/2023

Dermatology and Therapy 8/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.